Drug Trial Radar · NCT06731478
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
726
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Jun 1, 2028
Study completion Feb 1, 2030
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS \<1 gastric or GEJ cancer.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
Trastuzumab DeruxtecanDrug
T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
pembrolizumabDrug
Pembrolizumab will be administered at a dose of 200 mg IV Q3W
TrastuzumabDrug
Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W
ChemotherapyDrug
For Arms M1 and E1: 5-FU or capecitabine will be administered. For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From date of randomization to the date of radiographic disease progression or death due to any cause, up to 59 months
Locations
250 sites in 26 countries. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut · Not yet recruiting
Orchard Healthcare Research Inc.
Skokie, Illinois · Recruiting
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas · Not yet recruiting
Maryland Oncology Hematology, P.A.
Silver Spring, Maryland · Not yet recruiting
Tufts Medical Center
Boston, Massachusetts · Recruiting
University of Michigan Comprehensive Cancer Center Michigan Medicine
Ann Arbor, Michigan · Recruiting
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota · Withdrawn
Memorial Sloan Kettering Cancer Center - MAIN
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Providence Portland Medical Center
Portland, Oregon · Recruiting
Penn State University Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Prisma Health Cancer Institute, ITOR, CRU
Greenville, South Carolina · Recruiting
Tennessee Oncology Nashville Midtown
Nashville, Tennessee · Withdrawn
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Texas Oncology, P.A. - Tyler
Tyler, Texas · Not yet recruiting
Virginia Oncology Associates
Norfolk, Virginia · Not yet recruiting
Blue Ridge Cancer Care
Roanoke, Virginia · Not yet recruiting
Wenatchee Valley Hospital & Clinics
Wenatchee, Washington · Withdrawn
CEMIC Ciudad Autonoma
Buenos Aires, Argentina · Not yet recruiting
Instituto Medico Especializado Alexander Fleming
Buenos Aires, Argentina · Recruiting
Clinica Universitaria Privada Reina Fabiola
Córdoba, Argentina · Recruiting
Centro de Investigaciones Medicas Mar del Plata
Mar del Plata, Argentina · Recruiting
Instituto Medico de la Fundacion Estudios Clinicos
Rosario, Argentina · Recruiting
Flinders Medical Centre
Bedford Park, Australia · Recruiting
Monash Medical Centre Clayton
Clayton, Australia · Recruiting
Townsville University Hospital
Douglas, Australia · Recruiting
Peter MacCallum Cancer Centre
North Melbourne, Australia · Recruiting
GenesisCare North Shore (Oncology)
St Leonards, Australia · Recruiting
St John of God Subiaco Hospital
Subiaco, Australia · Recruiting
Wollongong Hospital
Wollongong, Australia · Recruiting
LKH - Universitaetsklinikum Graz
Graz, Austria · Recruiting
Medizinische Universität Innsbruck
Innsbruck, Austria · Recruiting
Medizinische Universität Wien
Vienna, Austria · Recruiting
St. Josef Krankenhaus Wien
Vienna, Austria · Recruiting
Landesklinikum Wiener Neustadt
Wiener Neustadt, Austria · Recruiting
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
AZ Sint-Lucas
Bruges, Belgium · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Centre Hospitalier Universitaire de Liege
Liège, Belgium · Recruiting
Showing 40 of 250 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.